Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients.

Haupt DW, Fahnestock PA, Flavin KA, Schweiger JA, Stevens A, Hessler MJ, Maeda J, Yingling M, Newcomer JW.

Neuropsychopharmacology. 2007 Dec;32(12):2561-9. Epub 2007 Mar 21.

2.

Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.

Smith RC, Lindenmayer JP, Davis JM, Kelly E, Viviano TF, Cornwell J, Hu Q, Khan A, Vaidhyanathaswamy S.

J Clin Psychiatry. 2009 Nov;70(11):1501-13. doi: 10.4088/JCP.08m04446yel. Epub 2009 Oct 6.

PMID:
19814947
3.

Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.

Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC.

Arch Gen Psychiatry. 2005 Jan;62(1):19-28.

PMID:
15630069
4.

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia.

Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G.

Arch Gen Psychiatry. 2002 Apr;59(4):337-45. Review.

PMID:
11926934
5.

Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.

Ader M, Garvey WT, Phillips LS, Nemeroff CB, Gharabawi G, Mahmoud R, Greenspan A, Berry SA, Musselman DL, Morein J, Zhu Y, Mao L, Bergman RN.

J Psychiatr Res. 2008 Oct;42(13):1076-85. doi: 10.1016/j.jpsychires.2008.01.004. Epub 2008 Feb 25.

6.

Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.

Henderson DC, Fan X, Sharma B, Copeland PM, Borba CP, Freudenreich O, Cather C, Evins AE, Goff DC.

J Psychiatr Pract. 2009 Jul;15(4):251-61. doi: 10.1097/01.pra.0000358312.99233.ef.

7.

Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis.

Henderson DC, Copeland PM, Borba CP, Daley TB, Nguyen DD, Cagliero E, Evins AE, Zhang H, Hayden DL, Freudenreich O, Cather C, Schoenfeld DA, Goff DC.

J Clin Psychiatry. 2006 May;67(5):789-97.

PMID:
16841629
8.

Plasma leptin and adiposity during antipsychotic treatment of schizophrenia.

Haupt DW, Luber A, Maeda J, Melson AK, Schweiger JA, Newcomer JW.

Neuropsychopharmacology. 2005 Jan;30(1):184-91.

9.

Atypical antipsychotics and glucose homeostasis.

Bergman RN, Ader M.

J Clin Psychiatry. 2005 Apr;66(4):504-14. Review.

PMID:
15816794
10.

Relationship between insulin resistance, dyslipidaemia and positive symptom in Chinese antipsychotic-naive first-episode patients with schizophrenia.

Chen S, Broqueres-You D, Yang G, Wang Z, Li Y, Wang N, Zhang X, Yang F, Tan Y.

Psychiatry Res. 2013 Dec 30;210(3):825-9. doi: 10.1016/j.psychres.2013.08.056. Epub 2013 Oct 7.

PMID:
24113122
11.

Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study.

Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, Marcy P, Addington J, Estroff SE, Robinson J, Penn DL, Azrin S, Goldstein A, Severe J, Heinssen R, Kane JM.

JAMA Psychiatry. 2014 Dec 1;71(12):1350-63. doi: 10.1001/jamapsychiatry.2014.1314.

PMID:
25321337
12.
13.

Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders.

Cohen D, Stolk RP, Grobbee DE, Gispen-de Wied CC.

Diabetes Care. 2006 Apr;29(4):786-91.

PMID:
16567816
14.

Hyperglycemia and antipsychotic medications.

Haupt DW, Newcomer JW.

J Clin Psychiatry. 2001;62 Suppl 27:15-26; discussion 40-1. Review.

15.

Relationship between body mass index and insulin resistance in patients treated with second generation antipsychotic agents.

Kim SH, Nikolics L, Abbasi F, Lamendola C, Link J, Reaven GM, Lindley S.

J Psychiatr Res. 2010 Jun;44(8):493-8. doi: 10.1016/j.jpsychires.2009.11.007. Epub 2009 Dec 3.

16.

Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.

Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, He YQ, Liu YJ, Chen JD, Li LH.

JAMA. 2008 Jan 9;299(2):185-93. doi: 10.1001/jama.2007.56-b.

PMID:
18182600
17.

Abdominal adiposity assessed by dual energy X-ray absorptiometry provides a sex-independent predictor of insulin sensitivity in older adults.

Lee CC, Glickman SG, Dengel DR, Brown MD, Supiano MA.

J Gerontol A Biol Sci Med Sci. 2005 Jul;60(7):872-7.

PMID:
16079210
18.

Prediabetic increase in hemoglobin A1c compared with impaired fasting glucose in patients receiving antipsychotic drugs.

Manu P, Correll CU, Wampers M, van Winkel R, Yu W, Mitchell AJ, De Hert M.

Eur Neuropsychopharmacol. 2013 Mar;23(3):205-11. doi: 10.1016/j.euroneuro.2012.05.002. Epub 2012 May 29.

PMID:
22652493
19.

Adiposity-independent hypoadiponectinemia as a potential marker of insulin resistance and inflammation in schizophrenia patients treated with second generation antipsychotics.

Sapra M, Lawson D, Iranmanesh A, Varma A.

Schizophr Res. 2016 Jul;174(1-3):132-136. doi: 10.1016/j.schres.2016.04.051.

PMID:
27211515
20.

Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder.

Vincenzi B, Greene CM, Ulloa M, Parnarouskis L, Jackson JW, Henderson DC.

J Psychiatr Pract. 2016 May;22(3):175-82. doi: 10.1097/PRA.0000000000000149.

Supplemental Content

Support Center